Phage therapy shows potential for treating prosthetic joint infections
Bacteriophages, or phages, may play a significant role in treating complex bacterial infections in prosthetic joints, according to new Mayo Clinic research. The findings suggest phage therapy could provide a potential treatment for managing such infections, including those involving antibiotic-resistant microbes.
The research is published in the July issue of Clinical Infectious Diseases.
“The treatment for chronic prosthetic joint infection has been surgery plus antibiotics, with surgery being the backbone of therapy. When these efforts fail, there can be significant suffering, loss of limb, even death,” says author Gina Suh, M.D. (INFD ’19), Division of Infectious Diseases, Mayo Clinic in Rochester.. “Phage therapy has the potential to be paradigm-shifting in how we treat infections in this era of increasing medical device use and antibiotic resistance.”
Phages are naturally occurring viruses found throughout the earth that target and kill specific bacterial cells, including those that have grown resistant to multiple antibiotics. The microscopic organisms, numbering in the billions, destroy bacteria by injecting their DNA or RNA into the bacteria to replicate and burst the cells open.
Although phage therapy is new to Mayo Clinic, the bacterial predators were discovered more than a century ago, predating antibiotics. Today, much of the basic science of phages remains to be discovered.
Dr. Suh oversaw the first phage treatment at Mayo Clinic in June 2019, when a 62-year-old man was facing potential amputation after multiple failed courses of antibiotics and surgery. The intravenous use of phage therapy was approved by the Food and Drug Administration on a compassionate-use basis.
“We started phage therapy as kind of a last-ditch effort to save his limb, and the patient responded beautifully,” Dr. Suh says. “He has remained asymptomatic after completing treatment and he experienced no adverse effects.”
The patient’s infection involved a biofilm that formed on his knee-joint replacement device — a common complication among the millions of people worldwide who undergo life-enhancing joint replacements every year.
Study co-author Robin Patel, M.D. (I ’92, INFD ’95, CM ’96), Division of Clinical Microbiology at Mayo Clinic in Rochester, says biofilms are communities of bacteria held together in a slimelike substance and that growth in biofilms enables bacteria to evade the effects of many antibiotics.
“When bacteria grow as biofilms on surfaces, such as joint replacement devices, bacteria are difficult to eradicate because being in biofilm state makes them resistant to many of the antibiotics that would otherwise work against them,” says Dr. Patel, director of Mayo Clinic’s Infectious Diseases Research Laboratory.
Dr. Patel uses proteomic analysis to identify a patient’s bacterium to begin the process of matching it with a phage.
“We then test a collection of phage against that particular patient’s species of bacteria to determine which might work best,” Dr. Patel says. “We’re looking for the ability of phage to either kill or keep these bacteria from growing as a measure of activity.”
She says as the world faces a growing public health threat from drug-resistant bacterial infections, and that it is possible that phage therapy could save lives, but more study is needed.
“There have been several patients who have been treated with phage with promising outcomes, but as a scientist, a single case like ours, or even a collection of single cases, is not enough to prove that a therapy is active,” Dr. Patel says.
The next step in the study is to expand the clinical use of phage therapy on prosthetic-joint infections of the hip and knee. Mayo Clinic is launching a two-year clinical trial later this year to continue to evaluate phage therapy in the treatment of infectious diseases.
This research was also supported by Stanford University School of Medicine; Adaptive Phage Therapeutics, and the Naval Medical Research Center.
The research was funded in part by the Congressionally Directed Medical Research Program (Work Unit Number A1427), Naval Medical Research Center, and by the Mayo Clinic CTSA through grant number UL1TR002377 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health.